GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (NAS:LNTH) » Definitions » Total Assets

Lantheus Holdings (Lantheus Holdings) Total Assets : $1,831 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Total Assets?

Lantheus Holdings's Total Assets for the quarter that ended in Mar. 2024 was $1,831 Mil.

Warning Sign:

If a company builds assets at 27.2% a year, faster than its revenue growth rate of 15.5% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Lantheus Holdings's average Total Assets Growth Rate was 26.70% per year. During the past 3 years, the average Total Assets Growth Rate was 5.90% per year. During the past 5 years, the average Total Assets Growth Rate was 27.20% per year. During the past 10 years, the average Total Assets Growth Rate was 18.80% per year.

During the past 13 years, Lantheus Holdings's highest 3-Year average Total Assets Growth Rate was 42.50%. The lowest was -9.80%. And the median was 15.20%.

Total Assets is connected with ROA %. Lantheus Holdings's annualized ROA % for the quarter that ended in Mar. 2024 was 30.11%. Total Assets is also linked to Revenue through Asset Turnover. Lantheus Holdings's Asset Turnover for the quarter that ended in Mar. 2024 was 0.21.


Lantheus Holdings Total Assets Historical Data

The historical data trend for Lantheus Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Total Assets Chart

Lantheus Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 405.92 869.82 863.78 1,321.26 1,651.15

Lantheus Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,349.28 1,337.72 1,521.61 1,651.15 1,831.33

Lantheus Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Lantheus Holdings's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=815.892+835.257
=1,651

Lantheus Holdings's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=945.54+885.794
=1,831

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantheus Holdings  (NAS:LNTH) Total Assets Explanation

Total Assets is connected with ROA %.

Lantheus Holdings's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=524.264/( (1651.149+1831.334)/ 2 )
=524.264/1741.2415
=30.11 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Lantheus Holdings's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=369.975/( (1651.149+1831.334)/ 2 )
=369.975/1741.2415
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Lantheus Holdings Total Assets Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings (Lantheus Holdings) Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Executives
Andrea Sabens officer: Chief Accounting Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Marshall Robert J. Jr. officer: CFO and Treasurer C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Paul Blanchfield officer: Chief Commercial Officer C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862
Mary Anne Heino director, officer: CEO and President C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Daniel Niedzwiecki officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Etienne Montagut officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Sam R Leno director C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760
Brian A Markison director 501 FIFTH STREET, BRISTOL TN 37620
Jean-claude Provost officer: Chief Medical Officer C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Carol Walker officer: Senior Vice President, Quality C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Ying Vivian Yao officer: Chief Human Resources Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
John J. Bolla director C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862